Confident of quickly adapting vaccine for Omicron: BioNTech CEO

Published On 2021-12-05 05:30 GMT | Update On 2021-12-05 05:30 GMT

Frankfurt: Germany's BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, its CEO Ugur Sahin said, adding that despite the mutation shots should continue to protect people against severe disease.

BioNTech and Pfizer Inc together produced one of the first vaccines against Covid-19, with well over 2 billion doses already given to protect people around the world.

There are concerns that the vaccines might not work as well against the Omicron variant which emerged last month.

"This variant might be able to infect vaccinated people. We anticipate that infected people who have been vaccinated will still be protected against severe disease," Sahin said in an interview during the Reuters Next conference on Friday.

The BioNTech CEO, whose work until the emergence of the Covid-19 coronavirus in 2020 was focused on cancer, said that the new variant had emerged sooner than he had anticipated.

"This highly mutant virus came earlier than I had expected. I had expected sometime next year and it's already with us."

Sahin also said that mutations in the virus meant it was more likely that annual vaccinations would be the norm, as is the case with seasonal flu, and that a new vaccine would be needed against Covid-19, although it was not yet clear when.

"I believe in principle at a certain timepoint we will need a new vaccine against this new variant. The question is how urgent it needs to be available," Sahin said.

Much remains unknown about Omicron, which was first detected in southern Africa last month and has been spotted in at least two dozen countries, just as parts of Europe were already grappling with a wave of infections of the Delta variant.

"We expect this variant might be able to infect vaccinated people and this variant will most likely be able to infect people with high exposure. That is one of the things that is now getting more and more clear. It is not clear whether this variant produces more severe disease," Sahin said.

Asked how infectious the Omicron variant might be, Ozlem Tureci, BioNTech's chief medical officer and its co-founder said: "This is something we have to learn with the passage of time and with the passage of time i mean really in daily, weekly horizon and experts are monitoring that closely."

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Confident of quickly adapting vaccine for Omicron: BioNTech CEO

Similar News

Sun Pharma Agrees To Rs 1,654 Cr Settlement In U.S. Pricing Row

No Special Price for Novel Pack: NPPA Panel Turns Down Sun Pharma's Amoxicillin-Clavulanic Formulation

CDSCO Panel Seeks Safety Data on 5% Lenalidomide TDS Before Clearing 8% Patch Trial

Dr Reddy's Labs plans to roll out cheaper Wegovy copycat across 87 countries in 2026: CEO

Action taken against 694 manufacturing units since 2022: Minister

J&J Imbruvica gains EU approval for untreated Mantle Cell Lymphoma in transplant eligible patients

Shilpa Medicare arm to infuse USD 2 million in Alveolus Bio

NPPA Panel Rejects Dr Reddy's Omez ODT Plea For Seperate Price, Finds No Therapeutic Edge